Unknown

Dataset Information

0

Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.


ABSTRACT: The prostaglandin E2 receptor, EP2, plays an important role in physiology and in a variety of pathological conditions. Studies indicate that EP2 is pro-inflammatory in chronic peripheral and central nervous system disease and cancer models. Thus, targeting the EP2 receptor with small molecules could be a therapeutic strategy for treating inflammatory diseases and cancer. We recently reported a novel class of competitive antagonists of the EP2 receptor. However, earlier leads displayed low selectivity against the DP1 prostanoid receptor, moderate plasma half-life, and low aqueous solubility, which renders them suboptimal for testing in animal models of disease. We now report a novel compound TG8-69, which has suitable drug-like properties. We present synthesis, lead-optimization studies, pharmacological characterization, and anti-inflammatory properties of this compound that support its use in chronic peripheral inflammatory diseases, including rheumatoid arthritis, endometriosis, and cancer, in which EP2 appears to play a pathogenic role.

SUBMITTER: Ganesh T 

PROVIDER: S-EPMC6633905 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Peripherally Restricted, Highly Potent, Selective, Aqueous-Soluble EP2 Antagonist with Anti-Inflammatory Properties.

Ganesh Thota T   Banik Avijit A   Dingledine Ray R   Wang Wenyi W   Amaradhi Radhika R  

Molecular pharmaceutics 20181115 12


The prostaglandin E<sub>2</sub> receptor, EP2, plays an important role in physiology and in a variety of pathological conditions. Studies indicate that EP2 is pro-inflammatory in chronic peripheral and central nervous system disease and cancer models. Thus, targeting the EP2 receptor with small molecules could be a therapeutic strategy for treating inflammatory diseases and cancer. We recently reported a novel class of competitive antagonists of the EP2 receptor. However, earlier leads displayed  ...[more]

Similar Datasets

| S-EPMC7394479 | biostudies-literature
| S-EPMC10108358 | biostudies-literature
| S-EPMC6912869 | biostudies-literature
| S-EPMC8020795 | biostudies-literature
| S-EPMC5633609 | biostudies-literature
| S-EPMC8033769 | biostudies-literature
| S-EPMC6697865 | biostudies-literature
| S-EPMC4025874 | biostudies-other
| S-EPMC6580551 | biostudies-literature
| S-EPMC7607848 | biostudies-literature